Clinical Outcomes from Tamoxifen Drug-herb Interactions

Campos Graça, M. Cupido, R. Tavares, R. Consul
{"title":"Clinical Outcomes from Tamoxifen Drug-herb Interactions","authors":"Campos Graça, M. Cupido, R. Tavares, R. Consul","doi":"10.15344/2456-3501/2018/140","DOIUrl":null,"url":null,"abstract":"Background: Tamoxifen is an important drug in chemotherapy being part of various protocols in cancer treatment, but is not universally effective even when used before surgery or in preventing recurrence. Pharmacogenetic variability in drug metabolism is one possible mechanism of treatment failure. We hypothesize that Drug-Herb Interactions (DHI) contribute in disease outcomes, nevertheless the functional single nucleotide polymorphisms in drug metabolizing enzymes that activate cytochrome enzymes. Methods: We performed a retrospective study in the last 9 years of clinical cases enrolled in follow up of Observatory of Drug-Herb Interactions, University of Coimbra - Portugal (www.oipm.uc.pt), and the data collected will be discussed in this paper. Data obtained from PubMed and from PubChem Compounds with preference given to the data obtained during the last 10 years, was also obtained. The search terms were varied depending of the Clinical situation. Results: From our experience, in order to avoid the major predictable DHI more observational trials should be carried out for therapeutic protocols associated to tamoxifen. The most consumed, fruits and vegetables, medicinal plants and other natural products associated to the intake of tamoxifen were, for example, Orange and Better juice, Aloe, Geranium, Saint John Wort leaves and flowers, roots as Astragalus, Curcuma, Ginger, Ginseng, Rehmanniae and Valeriana, mushrooms as Coriolus, Maitake, Shiitake and Reishi. Conclusions: Based on the major compounds involved in those products will be predictable how to advice patients doing this kind of treatment and follow a possible therapy failure, or even a toxic event. Our group did a flyer with the main possible interactions selected for DHI with Tamoxifen. This it will be given to patients doing therapy with tamoxifen, helping them to be a aware of the situation and involving all in the resolution for a better outcome (it will be available in our website as other materials for download already posted there).","PeriodicalId":344260,"journal":{"name":"International Journal of Clinical Pharmacology & Pharmacotherapy","volume":"96 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Pharmacology & Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15344/2456-3501/2018/140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Tamoxifen is an important drug in chemotherapy being part of various protocols in cancer treatment, but is not universally effective even when used before surgery or in preventing recurrence. Pharmacogenetic variability in drug metabolism is one possible mechanism of treatment failure. We hypothesize that Drug-Herb Interactions (DHI) contribute in disease outcomes, nevertheless the functional single nucleotide polymorphisms in drug metabolizing enzymes that activate cytochrome enzymes. Methods: We performed a retrospective study in the last 9 years of clinical cases enrolled in follow up of Observatory of Drug-Herb Interactions, University of Coimbra - Portugal (www.oipm.uc.pt), and the data collected will be discussed in this paper. Data obtained from PubMed and from PubChem Compounds with preference given to the data obtained during the last 10 years, was also obtained. The search terms were varied depending of the Clinical situation. Results: From our experience, in order to avoid the major predictable DHI more observational trials should be carried out for therapeutic protocols associated to tamoxifen. The most consumed, fruits and vegetables, medicinal plants and other natural products associated to the intake of tamoxifen were, for example, Orange and Better juice, Aloe, Geranium, Saint John Wort leaves and flowers, roots as Astragalus, Curcuma, Ginger, Ginseng, Rehmanniae and Valeriana, mushrooms as Coriolus, Maitake, Shiitake and Reishi. Conclusions: Based on the major compounds involved in those products will be predictable how to advice patients doing this kind of treatment and follow a possible therapy failure, or even a toxic event. Our group did a flyer with the main possible interactions selected for DHI with Tamoxifen. This it will be given to patients doing therapy with tamoxifen, helping them to be a aware of the situation and involving all in the resolution for a better outcome (it will be available in our website as other materials for download already posted there).
他莫昔芬药物-草药相互作用的临床结果
背景:他莫昔芬是一种重要的化疗药物,是各种癌症治疗方案的一部分,但即使在手术前使用或预防复发时也不是普遍有效。药物代谢的药物遗传变异是治疗失败的一个可能机制。我们假设药物-草药相互作用(DHI)有助于疾病结果,然而,激活细胞色素酶的药物代谢酶的功能单核苷酸多态性。方法:对葡萄牙科英布拉大学药物-草药相互作用观察站(www.oipm.uc.pt)近9年随访的临床病例进行回顾性研究,并对收集到的数据进行讨论。从PubMed和PubChem化合物中获得的数据,优先考虑最近10年获得的数据,也被获得。搜索词根据临床情况而变化。结果:根据我们的经验,为了避免主要的可预测的DHI,应该对与他莫昔芬相关的治疗方案进行更多的观察性试验。食用最多的水果和蔬菜,药用植物和其他与摄入他莫昔芬有关的天然产品有,例如,橙子和更好的果汁,芦荟,天竺葵,圣约翰草的叶子和花,根茎如黄芪,姜黄,姜,人参,地黄和缬草,蘑菇如Coriolus,舞茸,香菇和灵芝。结论:根据这些产品中涉及的主要化合物,可以预测如何建议患者进行这种治疗,并跟踪可能的治疗失败,甚至是毒性事件。我们小组做了一份传单,列出了他莫昔芬与DHI的主要可能相互作用。它将提供给接受他莫昔芬治疗的患者,帮助他们了解情况,并参与到解决方案中,以获得更好的结果(它将在我们的网站上提供,其他材料已经发布在那里)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信